BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 24, 2023, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of d
Source link